Pharmaceuticals, Healthcare, and Innovation by Eli Lilly
Eli Lilly announces third-quarter 2026 results: Can LLY break above $1,320?
Eli Lilly announced its third-quarter 2026 results. The stock edges higher on the day, trading at $1,289.Eli Lilly announced its results for the third quarter of 2026. The update came directly ...
Eli Lilly breaks ground on new Goochland facility as stock rises 3.4%
Eli Lilly announced it has started construction on its second U.S. manufacturing facility in two months, expanding its capacity for cancer drug production and planning 650 new high-wage jobs in ...
Eli Lilly presents positive one-year results for ulcerative colitis: Can LLY break above $1,275?
Eli Lilly presented one-year Phase 3 data in children and adolescents with ulcerative colitis at UEGWeek, reporting positive results from its SHINE-2 study. Shares edge higher on the day, trading ...
Eli Lilly breaks ground on new Houston manufacturing site as stock edges higher
Eli Lilly announced a $6.5 billion groundbreaking for a new manufacturing facility in Houston, Texas, as part of its $50 billion push to expand U.S. drug production and job creation. Shares edge ...
Eli Lilly receives FDA clearance for type 2 diabetes drug: Will LLY hold $1,171 support?
The FDA approved a new use for an Eli Lilly medicine to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for these complications. The stock is ...
Eli Lilly stock holds at $1,117.66 as technical factors limit downside amid illustrative update
Eli Lilly reported second quarter results that it said show momentum and progress on its business and innovation pipeline. At the same time, Eli Lilly stock edges lower on the day, trading at ...
Eli Lilly stock drops 1.12 percent as FDA grants breakthrough therapy
Eli Lilly says the FDA has granted Breakthrough Therapy designation for a potential treatment option for patients with a certain form of advanced pancreatic cancer who have been previously ...
Eli Lilly stock trades down to $1,143 as FDA approves new eczema dosing, Eli Lilly and Company
Eli Lilly said the U.S. FDA has approved a new dosing option for its moderate-to-severe atopic dermatitis treatment.The company said this approval could have implications for patients with eczema. ...
Eli Lilly slides slightly to $1,143.53 as ADA2026 event concludes, Eli Lilly and Company posts
Eli Lilly marked the conclusion of #ADA2026. The event offered important reminders about the significance of science and its intended beneficiaries.Eli Lilly shared its perspective using the ...
Eli Lilly stock rises to $1,156 after superior A1C and weight loss results in clinical trials
Eli Lilly reported new clinical trial results showing its oral GLP-1 provided superior A1C control and weight loss. The results cover three clinical trials.Eli Lilly directed readers to its ...
Eli Lilly and Company details up to 30 pound weight loss in obesity drug studies for menopause
Eli Lilly said women at every stage of menopause saw meaningful weight loss in post-hoc analyses of two studies of one of its obesity medicines, according to results presented at #ADA2026.The ...
Eli Lilly stock edges lower despite promising diabetes trial data presented at ADA 2026
Eli Lilly said adults with type 2 diabetes on its investigational triple agonist saw significant A1C reductions at 40 weeks in the TRANSCEND-T2D-1 trial.Eli Lilly presented results today at ...
Knee osteoarthritis and sleep apnea trial data underpin steady trading for Eli Lilly stock
Eli Lilly reported that its investigational triple agonist achieved a 73% reduction in knee osteoarthritis pain at the 12 mg dose in the TRIUMPH-1 study.The same drug reduced moderate-to-severe ...
Eli Lilly stock slips as new Phase 3 obesity drug data released, Eli Lilly and Company reports
Eli Lilly said its investigational triple agonist met all primary endpoints in the TRIUMPH-1 Phase 3 trial at ADA 2026.Patients on the 12 mg dose lost an average of 70 pounds, or 28.3%, over 80 ...
Eli Lilly stock rises 1.81 percent as company looks ahead to #ADA2026 event, Eli Lilly and Company
Eli Lilly said the future of obesity treatment will require medicines tailored to individuals at different stages of their treatment journeys.Rachel Batterham shared views on the need for ...
